-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Major Events of Shijiazhuang Sihua Pharmaceutical Group in 2024
Category:
发布时间：2024-07-15
【概要描述】
Turning the page of time, the hands of the annual rings point to July—half past is behind us, and half ahead holds our hopes and aspirations.
Looking back on the first half of the year just concluded, the employees of Sino-Pharm have never ceased their relentless pursuit. Driven by innovation and grounded in quality, the Group, with the care, support, and strong backing of Party committees and governments at all levels as well as upstream and downstream industry partners, has seen its innovative, high-performance ecosystem for integrated API–formulation development expand steadily. New products keep emerging, and drug R&D and market translation are in perfect harmony, continuously laying a solid foundation for the company’s innovative, high-quality growth.
The stars do not ask those who press on; history belongs to those who strive. Along this journey of steadfast progress, our confidence in forging a shared future has only grown stronger.
Turning the page of time, the hands of the annual rings point to July—half past, half promise.
Looking back at the just-concluded first half of the year, the employees of Sihua Pharmaceutical have never ceased their relentless pursuit on the path of progress. Driven by innovation and grounded in quality, the Group—supported by the caring attention and robust backing of Party committees and governments at all levels as well as upstream and downstream industry partners—has seen its innovative, high-performance ecosystem for integrated API–formulation development continue to expand. A steady stream of new products has emerged, with drug R&D and market translation operating in perfect harmony, thereby continuously laying a solid foundation for the company’s high-quality, innovation-driven growth.
The stars shine on no one in particular; history belongs to those who strive. Throughout our journey of relentless progress and perseverance, we have strengthened our confidence and resolve to move forward into the future. As we set our sights on even loftier goals, it is all the more imperative that we press ahead with unwavering determination and steadfast commitment. By turning sweat into reward and forging ahead through practical action, we will live up to the call of history, the demands of our times, and the preciousness of youth—and in doing so, we will undoubtedly deliver a remarkable report card for high-quality development in 2024.
Frequent Breakthroughs in R&D | obtain Approval of 46 new product dossiers
In the first half of this year, the Group received approval for a total of 46 new products, with R&D quality and efficiency significantly surpassing the level recorded during the same period last year. (As of July 6, the Group has now secured approval for a cumulative total of 52 new products this year.)
Innovation is surging, linking “pearls” into a “chain.” In recent years, the Group has taken meeting public health needs and industrial-chain demands as its starting point, continuously increasing investment and deepening strategic deployment. Through integrated development of active pharmaceutical ingredients and finished dosage forms, its product pipeline has grown increasingly rich and diversified. As of the first half of this year, the company boasts 321 finished dosage-form products, with 89 products across 120 specifications having either passed or been deemed to have passed the consistency evaluation; it also offers 60 bulk and specialty API products, thereby powerfully enabling the company to move up the value chain toward the mid- to high-end segments of the industry. (As of July 6, the company’s portfolio has expanded to 326 finished dosage-form products, with 94 products across 126 specifications having either passed or been deemed to have passed the consistency evaluation.)
Accelerate Diversified Innovation | Group’s Bosheng Medical Devices Research Institute Officially Established
On January 6, the Pharmaceutical Packaging Materials Research Institute of Jiangsu Bosheng Medical New Materials Co., Ltd., a subsidiary of the Group, was officially inaugurated and put into operation, laying the foundation for establishing a hub of innovation in pharmaceutical packaging materials and accelerating the development of a national-level enterprise technology center.
As a leading enterprise in China’s pharmaceutical packaging materials sector, Bosheng Medical Materials holds a pioneering position in the fields of butyl rubber stoppers, multilayer co-extruded infusion films, and biopharmaceutical films. In recent years, while maintaining the competitive edge of its traditional products, the company has steadily intensified R&D efforts and market development for high-end, specialized-application, and forward-looking pharmaceutical packaging materials, thereby strengthening product–supply-chain integration and further enhancing product market penetration and coverage. New products such as bromobutyl rubber composite seals for pen-type injectors, X13B insulin gaskets, highly breathable cell-culture bag films, and stem-cell cryopreservation bag films have emerged as key growth drivers for the company’s business development.
Digital Intelligence Empowers Innovation | One application has been included in the MIIT’s first batch of information technology case studies.
On January 9, the Ministry of Industry and Information Technology released the first batch of 2023 exemplary products, applications, and service cases in next-generation information technology. Shijiazhuang Sihua Pharmaceutical’s “Innovative Application of the Intelligent Pharmaceutical Operations Collaborative Dispatch Platform” was selected as an “Innovative Leading Application Case for Industrial Internet Platforms—Networked Collaboration,” marking a new step and significant achievements for the Group in its digital transformation and development.
This innovative industrial internet platform project was developed in response to the practical needs of enterprise digital transformation and, since its implementation, has effectively propelled a new leap forward in corporate management and intelligent manufacturing. The Group will continue to advance its digital empowerment initiative, further accelerating the integrated development of next-generation information technologies with manufacturing, and leveraging digitalization and intelligence to drive high-quality, innovation-driven growth across the enterprise.
Patents Drive Development | Three Products Recognized as Among the First Batch of Patent-Intensive Products at the National Level
In the first half of this year, three products manufactured by the Group—sodium bicarbonate injection, bromhexine hydrochloride and glucose injection, and sodium chloride injection—were successfully included in the first national list of patent-intensive products.
“Patent-intensive products” primarily refer to products that possess multiple high-quality patents, rely heavily on patent protection in market competition, and enjoy strong competitive advantages—serving as a crucial bridge between the patent ecosystem and the marketplace. In the first batch of officially recognized patent-intensive products, a total of 26 products from 12 enterprises, including Shijiazhuang Sihua Pharmaceutical, were selected.
Significant Achievements in Green Pharmaceutical Manufacturing | Guangxiang Pharmaceutical Group Obtains Cangzhou’s First “Carbon Certificate”
On March 13, Guangxiang Pharmaceutical, a subsidiary of the Group, was awarded Cangzhou City’s first carbon footprint certification certificate. This milestone underscores the company’s significant progress in advancing the “dual carbon” goals and achieving green development.
In recent years, Guangxiang Pharmaceutical Group has been driven by innovation and seized the strategic opportunities presented by the Beijing–Tianjin–Hebei coordinated development initiative. The company has integrated the concept of green development throughout its entire production and business operations, actively enhanced the green manufacturing of active pharmaceutical ingredients, created and led demand through high-quality supply, continuously strengthened the appeal of its products in both domestic and international markets, and steadily bolstered its overall competitiveness. In 2023, Guangxiang Pharmaceutical was recognized as a “Green Factory” by the Ministry of Industry and Information Technology.
Young People Should Take the Lead | One post has been recognized as a National Model Post for Youth Safety in Production.
In March, the Central Committee of the Communist Youth League and the Ministry of Emergency Management recognized 486 organizations as National Model Posts for Youth Safety in Production for 2023, among which the “Packaging Position in the 207 Solid Dosage Workshop of the Manufacturing Center” of our Group was awarded the title of National Model Post for Youth Safety in Production for 2023.
According to reports, in their daily work the packaging team of Workshop 207 for Solid Preparations has taken the lead, rigorously aligning its practices with the requirements and standards of the initiative and benchmarking against actual production conditions. Leveraging initiatives such as “Safety Production Month,” “Fire Safety Public Awareness Month,” and themed Youth League days, the team has continuously enhanced all employees’ awareness of safety responsibilities and their operational skills, thereby effectively deepening and solidifying safety management. As a result, the Youth Safety Production Model Post program has been institutionalized, normalized, standardized, and scientifically grounded, with the aim of inspiring young workers to embrace the commitment of “Safety First—Youth Take the Lead” and encouraging them to actively engage in the enterprise’s safety production efforts.
A Tribute to the Role Models Around Us | Two R&D Researchers Receive Prestigious Awards
On the eve of International Labor Day, the All-China Federation of Trade Unions and the Hebei Provincial Federation of Trade Unions solemnly commended recipients of the 2024 National May Day Labor Awards—namely, the May Day Labor Medals, May Day Labor Certificates, Advanced Collectives, and Outstanding Individuals—as well as provincial Model Workers, Advanced Workers, and Advanced Collectives. Among them, Xia Guolong and Wei Saili, researchers from our group, were awarded the National May Day Labor Medal and the title of Hebei Provincial Model Worker, respectively. Earlier this year, Wei Saili was also named one of the “Top Ten People Who Moved the Provincial Capital.”
Since the advent of the new era, the Group has continuously achieved new milestones in its innovative, high-quality development. Xia Guolong and Wei Saili, as outstanding representatives of the Group’s R&D innovation, have long been at the forefront of scientific research, demonstrating a tireless work ethic, a selfless commitment to their mission, and a rigorous, pragmatic scientific approach. Under their leadership, their teams have tackled tough challenges and overcome obstacles, making remarkable contributions to the enterprise’s innovative, high-quality growth. To date, more than ten individuals from the Group have been awarded national, provincial, and municipal labor honors, serving as role models within the organization whom all employees can learn from, emulate, and strive to match.
Strengthening the Foundation of Quality | The Group Launches the “2024 Quality Improvement Year” Initiative
In 2024, in order to enhance product quality and elevate employee skill levels, the Group has designated this year as the “Quality Enhancement Year” and has organized a series of initiatives under the theme “Innovation Leads the Way, Continuous Pursuit of Excellence; Quality Wins, Forging Brilliance.”
According to reports, the “2024 Quality Enhancement Year” initiative is closely aligned with the company’s key quality management priorities—“adhering to quality-driven customer satisfaction and ensuring robust accountability; refining the quality management system and pursuing continuous improvement”—and leverages a variety of activities, including establishing quality management innovation studios, conducting professional skills competitions, and delivering practical training on quality regulations, to vigorously foster a corporate culture that values quality. The goal is to embed quality standards and principles deeply in the minds of all employees, guide production and management practices, and, through superior product quality and service, ensure the Group’s innovative, high-quality development proceeds steadily and sustainably.
Honor Bears Witness to Strength | Four Pharmaceuticals Ranked Among the Top 50 Chinese Chemical Pharmaceutical Companies
On June 25, the organizing committee of the MiSi Conference unveiled the highly anticipated “2023 Top 100 Chinese Pharmaceutical Industry Rankings.” The Group was ranked among the Top 100 Chinese Chemical Pharmaceutical Enterprises for 2023, coming in at No. 34—five places higher than the previous year.
In recent years, the Group has focused its strategic deployment and R&D efforts on key therapeutic areas including anti-infectives, respiratory diseases, neurological disorders, cardiovascular and cerebrovascular conditions, gastrointestinal diseases, anesthesia, endocrinology, oncology, and dialysis. It has continuously advanced integrated development of active pharmaceutical ingredients (APIs) and finished dosage forms, proactively built an innovative, high-value ecosystem, and accelerated the research and development of high-end, complex generic drugs, innovative medicines, specialty APIs, pharmaceutical packaging materials, and products undergoing bioequivalence evaluation. As a result, the Group has established a distinctive product portfolio and gained new competitive advantages in the industry. In 2023, driven by product iteration and innovation, the Group secured approval for 88 new products, ranking among the top in the industry in terms of both submissions and approvals. These innovations have effectively strengthened the company’s supply structure, enhanced scale-driven growth, improved quality and efficiency, and elevated its industry influence and competitiveness to a new level.
Growing brand influence | Collection High-Quality Development of the Youth League Attracts Wide Attention
The group’s innovative efforts to accelerate the development of new-quality productive forces by vigorously researching, developing, and producing more “China-made high-quality medicines” have garnered extensive attention from mainstream news media.
In the first half of the year, numerous mainstream media outlets—including CCTV News, Xinhua News Agency, China International Radio, Hebei Daily, Hebei Radio and Television Station, Great Wall New Media, Hebei Economic Daily, Inner Mongolia Radio and Television Station, Hebei Workers’ Daily, Shijiazhuang Daily, and Shijiazhuang Radio and Television Station—conducted in-depth, multi-dimensional coverage of the Group’s R&D center and production workshops, highlighting the Group’s relentless pursuit of “height” and “innovation.” Headlines such as “R&D Innovation Sounds the ‘New Year Start-Up Call’,” “Digital Engine in Workshop 312 Accelerates ‘Smart Manufacturing,’” “Exploring the Group’s Innovative Practices in Chinese-style Modernization,” and “Unlocking the Potential of ‘Industrial AI’” vividly illustrated, through compelling real-world examples, the powerful momentum that the Group’s accelerated development of new-quality productive forces is injecting into its high-quality growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091